Back to CIFAS
Disaster & Science
Drugs & society homeIntroductionBackgroundNews indexAnalysesResourcesSearch

Cells of the Immune System

The various organs of the immune system are positioned throughout the body and include bone marrow, thymus, lymph nodes and spleen. The cells of the immune system consist of white blood cells, or leukocytes, which are formed in the bone marrow from stem cells so-called because a great variety of cells descend from them (see below). There are two kinds of leukocytes: Lymphocytes and phagocytes. Lymphocytes consist of B cells, T cells,h and natural killer cells (NK), and the major phagocytes include monocytes, macrophages and neutrophils. Phagocytes have many important roles in the immune response, but most significantly they initiate these responses by engulfing and digesting foreign substances (e.g., bacteria, viruses, foreign proteins), or antigens, that enter the body. Once digested, the antigen is exposed to specialized Iymphocytes (i.e., B cells and T cells) so that antibodies and effector T cells can be produced to help destroy any remaining antigens in the body. Antibodies are proteins produced by B cells that bind to antigens and promote antigen destruction. effector T cells include killer T cells which attack and kill antigen laden cells, and helper T cells, which secrete special proteins called cytokines that promote antigen elimination. Natural killer cells are specialized Iymphocytes that are also activated by antigen to either kill infected targets or secrete immunoregulatory cytokines.

h The B and T refer to where the cells mature, either in the bone marrow (B) or thymus (T).


The CB2 receptor gene, which is not expressed in the brain, is particularly abundant in immune tissues, with an expression level 10-100 times higher than that of CB1 In spleen and tonsils, the CB2 mRNAi content is equivalent to that of CB1 mRNA in the brain.48 The rank order, from high to low, of CB2 mRNA levels in immune cells is B-cells > natural killer cells >> monocytes > polymorphonuclear neutrophil cells > T8 cells in T4 cells. In tonsils, the CB2 receptors appear to be restricted to B-lymphocyte-enriched areas. In contrast, CB1 receptors are mainly expressed in the central nervous system and, to a lower extent, in several peripheral tissues such as adrenal gland, heart, lung, prostate, uterus, ovary, testis, bone marrow, thymus and tonsils.

Cannabinoid Receptors and Intracellular Action in Immune Cells

CB2 appears to be the predominant gene expressed in resting leukocytes.78, 112 The level of CB1 gene activity is normally low in resting cells but increases with cell activation.32 Thus the CB1 receptor might be important only when immune responses are stimulated, but the physiological relevance of this observation remains to be determined. Some of the cannabinoid effects observed in immune systems, especially at high drug concentrations, are likely mediated through non-receptor mechanisms, but these have not yet been identified.4

Ligand binding to either the CB1 or CB2 receptors inhibits adenylate cyclase, an enzyme that is responsible for cAMP production, and is, thus, an integral aspect of intracellular signal transduction (see figure 2.3).53, 79, 91, 122, 139, 151, 167 Increases in intracellular cAMP concentrations lead to immune enhancement, while decreases lead to an inhibition of immune responses.77 Cannabinoids inhibit the rise in intracellular cAMP that normally results from leukocyte activation, and this might be the pathway through which cannabinoids suppress immune cell functions.28, 74, 167 In addition, cannabinoids activate other molecular pathways such as the nuclear factor-kB pathway and therefore these signals might be modified in drug treated immune cells.33, 74

i After a gene is transcribed it is often spliced and modified into mRNA, or message RNA. The CB-2 mRNA is the gene "message" that moves from the cell nucleus into the cytoplasm where it will be translated into the receptor protein.


T and B Cells

When stimulated by antigen, lymphocytes (see box on Cells of the Immune System) first proliferate and then mature or differentiate to become potent effector cells, such as B cells that release antibodies or T cells that release cytokines. The normal T cell proliferation that is seen when human lymphocytes and mouse splenocytes (spleen cells) are exposed to antigens and mitogensj can be inhibited by THC, 11-OH-THC, cannabinol, and 2-AG, as well as synthetic cannabinoid agonists such as CP 55,940, WIN 55,212 and HU-210 61, 89, 93, 99, 127, 155 In contrast, one study testing anandamide revealed little or no effect on T-cell proliferation.93

However, these drug effects are variable, and depend on experimental conditions such as the experimental drug dose used, mitogen used, percent of serum in the culture, and timing of cannabinoid drug exposure. In general, lower doses of cannabinoids increase proliferation while higher doses suppress proliferation. Doses that are effective in suppressing immune function are typically greater than 10 µM in cell culture studies and greater than 5 mg/kg in whole animal studies.85 By comparison, at 0.05 mg/kg, people will experience the full psychoactive effects of THC; however, because of their high metabolic rates, small rodents frequently require drug doses that are 100-fold higher than doses needed for humans to achieve comparable drug effects. Thus, the immune effects of doses of cannabinoids higher than those ever experienced by humans, should be interpreted with caution.89, 93, 93, 127, 155

As with T cells, B cell proliferation can be suppressed by various cannabinoids, such as THC, 11-OH-THC and 2-AG, but B cell proliferation is more inhibited at lower drug concentrations than T cell proliferation.89, 93 Conversely, low doses of THC, CP 55,940 and WIN 55,212-2 increase B-cell proliferation in cultured human cells exposed to mitogen.35 This effect possibly involves the CB2 receptor, because the effect appears to be the same when the CB1 receptor was blocked by the antagonist, SR-141716A (which does not block the CB2 receptor). The reason for the differences in cell responsiveness to cannabinoids is probably due to differences in cell type and source; for example, B cells collected from mouse spleen might respond to cannabinoids somewhat differently than B cells from human tonsils.

jMitogens are substances that stimulate cell division (mitosis) and cell transformation.


Natural Killer Cells

Repeated injections of relatively low doses of THC (3 mg/kg/day 121 k) or two injections of a high dose (40 mg/kg86) suppress the ability of natural killer (NK) cells to destroy foreign cells in rats and mice. THC can also suppress natural killer cell cytolytic activity in cell cultures; 11-OH-THC, is even more potent.86 In contrast, THC doses below 10µM had no effect on natural killer cell activity in mouse cell cultures.98


Macrophages perform various functions including phagocytosis (ingestion and destruction of foreign substances), cytolysis, antigen presentation to lymphocytes, and production of a variety of active proteins involved in destroying microorganisms, tissue repair and modulation of immune cells. Those functions can be suppressed by THC doses similar to those capable of modulating lymphocyte functions (see above).88, 109


Cytokines are proteins produced by immune cells. When released from the producing cell they can alter the function of other cells they come in contact with. In a sense, they are like hormones. Thus, cannabinoids can either increase or decrease cytokine production depending upon experimental conditions.

Certain cytokines, such as interferon- and interleukin-2 (IL-2) are produced by T helper-1 (Th1) cells. These cytokines help to activate cell-mediated immunity and the killer cells that eliminate microbes from the body (see Box on cells of the immune system). When injected into mice, THC suppresses the production of those cytokines that modulate the host response to infection (see below).115 Cannabinoids also modulate interferons induced by viral infection,21 as well as other interferon inducers.85 Furthermore, in human cell cultures, interferon production can be increased by low concentrations, but decreased by high concentrations of either THC or cannabidiol. 6 In addition to Th1 cytokines, cannabinoids also modulate the production of cytokines such as interleukin-1 (IL-1), tumor necrosis factor (TNF), and interleukin-6 (IL-6). 145, 176 At 8 mg/kg, THC can increase the in vivo mobilization of serum acute phase cytokines including IL-1, TNF, and IL-6.90 Finally, although these studies suggest that cannabinoids can induce an increase in cytokines, other studies suggest that they can also suppress cytokine production.85 The different results might be due to different cell culture conditions or because different cell lines were studied.

k While 3 mg/kg would be a high dose for humans (see table 3.1); in rodents, it is a low dose for immunological effects, and a moderate dose for behavioral effects.


Antibody Production

Antibody production is an important measure of humoral immune function as contrasted with cellular (cell-mediated immunity). Antibody production can be suppressed in mice injected with relatively low doses of THC (>5 mg/kg) or HU210 (>0.05 mg/kg) and in mouse spleen cell cultures exposed to a variety of cannabinoids, including THC, 11-OH-THC, cannabinol, cannabidiol, CP 55,940, or HU-210.5, 6, 61, 78, 79, 84, 85, 142, 164 However, the inhibition of antibody response by cannabinoids was only observed when antibody-forming cells were exposed to T cell-dependent antigens (the responses require functional T cells and macrophages as accessory cells). Conversely, antibody responses to several T cell-independent antigens were not inhibited by THC, suggesting that the B cell is relatively insensitive to inhibition by cannabinoids.142

Resistance To Infection In Animals Exposed To Cannabinoids

Bacterial infections evaluated in mice demonstrated that THC can suppress resistance to infection, although the effect depends upon the dose and timing of drug administration. Mice pre-treated with THC (8 mg/kg) one day prior to infection with a sublethal dose of the pneumonia-causing bacteria, Legionella pneumophilia, and then treated again one day after the infection with THC, developed symptoms of cytokine-mediated septic shock and died; control mice that were not pre-treated with THC became immune to repeated infection and survived the bacterial challenge.90 If only one injection of THC was given or doses less than 5 mg/kg were used, all of the mice survived the initial infection, but failed to survive a subsequent challenge with a lethal dose of the bacteria; hence these mice failed to develop immune memory in response to the initial sublethal infection.87 Note that these are very high doses, and are considerably higher than doses experienced by marijuana users (see figure 3.1).115 In rats, doses of 4.0 mg/kg THC are aversive95

Few studies have been done to evaluate the effect of THC on viral infections, and this is an area that needs further study.20 Compared to healthy animals, THC might have greater immunosuppressive effects in animals whose immune systems are severely weakened. For example, a very high dose of THC (100 mg/kg) given twice, two days before and after herpes simplex virus infection, was shown to be a co-factor with herpes simplex virus in enhancing the progression to death in an immunodeficient mouse model infected with a leukemia virus.85 However, THC given as a single dose (100 mg/kg) two days before herpes simplex virus infection did not promote the progression to death in these animals. Hence, whether THC is immunosuppressive likely depends on the timing of THC exposure relative to an infection.


Anti-inflammatory Effects

As discussed above, cannabinoid drugs can modulate the production of cytokines, which are central to inflammatory processes in the body. In addition, several studies have shown directly that cannabinoids can be anti-inflammatory. For example, in rats with autoimmune encephalomyelitis (an experimental model used to study multiple sclerosis), cannabinoids were shown to attenuate the signs and the symptoms of central nervous system damage.100, 172 (Some believe that nerve damage associated with multiple sclerosis is caused by an inflammatory reaction.) Likewise, the cannabinoid, HU-211, was shown to suppress brain inflammation that resulted from closed head injury 146 or infectious meningitis 7 in studies on rats. HU211 is a synthetic cannabinoid that does not bind to cannabinoid receptors, and is not psychoactive,7 thus, without direct evidence, the effects of marijuana cannot be assumed to include those of HU-211. CT-3, another atypical cannabinoid, suppresses acute and chronic joint inflammation in animals.178 It is a nonpsychoactive, synthetic derivative of 11-THC-oic acid (a breakdown product of THC), and does not appear to bind to cannabinoid receptors. 129 Cannabichromene, a cannabinoid found in marijuana, has also been reported to have anti-inflammatory properties.173 No mechanism of action for possible anti-inflammatory effects of cannabinoids has been identified and the effects of these atypical cannabinoids and effects of marijuana are not yet established.

It is interesting to note that two reports of cannabinoid-induced analgesia are based on the ability of the endogenous cannabinoids, anandamide and PEA, to reduce pain associated with local inflammation that was experimentally induced by subcutaneous injections of dilute formalin.22, 73 Both THC and anandamide can increase serum levels of ACTH and corticosterone in animals.169 Those hormones are involved in regulating many responses in the body, including those to inflammation. The possible link between experimental cannabinoid-induced analgesia and reported anti-inflammatory effects of cannabinoids is important for potential therapeutic uses of cannabinoid drugs, but has not yet been established.

Conclusions regarding effects on immune system

Based on cell culture and animal studies, cannabinoids have been established as immunomodulators - that is, they increase some immune responses and decrease others. The variable responses depend upon experimental factors such as drug dose, timing of delivery, and type of immune cell examined.

Cannabinoids affect multiple cellular targets within the immune system and a variety of effector functions. Many of the effects noted above appear to occur at


concentrations of > 5 µM in vitro and > 5 mg/kg in vivo.l By comparison, a 5 mg injection of THC into a person (about 0.06 mg/kg) is enough to produce strong psychoactive effects. It should be emphasized, however, that little is known about the effects of chronic low dose exposure to cannabinoids on the immune system.

Another issue in need of further clarification involves the potential usefulness of cannabinoids as therapeutic agents in inflammatory diseases. Glucocorticoids have historically been used for these diseases, but non-psychotropic cannabinoids potentially have fewer side effects and might thus offer an improvement over glucocorticoids in treating inflammatory diseases.

Conclusions and Recommendations

Following the progress of the past fifteen years in understanding the effects of cannabinoids, research over the next decade is likely to reveal even more. It is interesting to compare how little we know about the cannabinoids with how much we know about the opiates (table 2.8). This table, in fact, suggests good reason for optimism about the future of cannabinoid drug development. Now that many of the basic tools of cannabinoid pharmacology and biology have been developed, one can expect to see rapid advances that can begin to match what is known for opiate systems in the brain.

Despite the tremendous progress in understanding the pharmacology and neurobiology of brain cannabinoid systems, this field is still in its early developmental stages. A key focus for future study is the neurobiology of endogenous cannabinoids. Establishing the precise brain localization - i.e.,., in which cells and where in those cannabinoids are found, cellular storage and release mechanisms, and uptake mechanisms will be crucial in determining the biological role of this system. Technology that will be crucial in establishing the biological significance of these systems will be broad based and include such research tools as the transgenic, or gene knockout mice, as have already been accomplished for various opioid receptor types.26 In 1997, both CB1 and CB2 receptor knockout mice were generated by a team of scientists at NIH, and a group in France has developed another strain of CB1 in receptor knockout mice.92

lIn vitro studies are those in which animal cells or tissue are removed and studied outside the animal; in vivo studies are those in which experiments are conducted in the whole animal.


Table 2.8 Historical comparisons between cannabinoids and opiates

Comparisons between cannabinoids and opiates
. Cannabinoids Opiates
Discovery of receptor existence 1988 (Howlett and Devane)36, 40 1973 (Pert and Snyder, Terenius, and Simon)123, 149, 162
Identification of receptor antagonist 1994 SR141716A (Rinaldi- Carmona)132 pre- 1973 Naloxone
Discovery of 1st endogenous ligand 1992 Anandamide (Devane And Mechoulam)37 1975 Met- and Leu-enkephalin (Hughes et al)70
1st Receptor cloned 1990 (Matsuda) 107 1992 (Evans et al. and Kieffer et al.)41, 82
Natural functions of cannabinoid / opiate systems Unknown Pain, reproduction, mood, movement, and others

There are several research tools that will greatly aid such investigations - in particular, a greater selection of agonists and antagonists that permit discrimination between the activation of CB1 versus CB2 receptors; hydrophilic agonists (that can be delivered to animals or cells more effectively than hydrophobic compounds). In the area of drug development, future progress should continue to provide more specific agonists and antagonists for CB1 and CB2 receptors, with varying potential for therapeutic uses.

There are certain areas that will provide keys to a better understanding of the potential therapeutic value of cannabinoids. For example, basic biology indicates a role for cannabinoids in pain and control of movement, which is consistent with a possible therapeutic role in these areas. The evidence is relatively strong for the treatment of pain, and intriguingly, although less well-established, for movement disorders. The neuroprotective properties of cannabinoids might prove therapeutically useful, although it should be noted that this is a new area and other, better studied, neuroprotective drugs have not yet been shown to be therapeutically useful. Cannabinoid research is clearly relevant not only to drug abuse, but also to


understanding basic human biology. Further, it offers the potential for the discovery and development of new, therapeutically useful drugs.

CONCLUSION: At this point, our knowledge about the biology of marijuana and cannabinoids allows us to make some general conclusions:

Cannabinoids likely have a natural role in pain modulation, control of movement, and memory.

The natural role of cannabinoids in immune systems is likely multifaceted and remains unclear.

The brain develops tolerance to cannabinoids.

Animal research demonstrates the potential for dependence, but this potential is observed under a narrower range of conditions than with benzodiazepines, opiates cocaine, or nicotine.

Withdrawal symptoms can be observed in animals, but appear to be mild compared to opiates or benzodiazepines, such as diazepam (Valium ®).

CONCLUSION: The different cannabinoid receptor types found in the body appear to play different roles in normal physiology. In addition, some effects of cannabinoids appear to be independent of those receptors. The variety of mechanisms through which cannabinoids can influence human physiology underlies the variety of potential therapeutic uses for drugs that might act selectively on different cannabinoid systems.

RECOMMENDATION: Research should continue into the physiological effects of synthetic and plant-derived cannabinoids and the natural function of cannabinoids found in the body. Because different cannabinoids appear to have different effects, cannabinoid research should include, but not be restricted to effects attributable to THC alone.

This chapter has summarized recent progress in understanding the basic biology of cannabinoids, and provides a foundation for the next two chapters which review studies on the potential health risks (chapter 3) and benefits of marijuana use (chapter 4).



1. Abood ME, Martin BR. 1996. Molecular neurobiology of the cannabinoid receptor. International Review of Neurobiology 39:197-221.

2. Abood ME, Sauss C, Fan F. Tilton CL, Martin BR. 1993. Development of behavioral tolerance to delta 9- T HC without alteration of cannabinoid receptor binding or mRNA levels in whole brain. Pharmacology, Biochemistry and Behavior 46:575-9.

3. Aceto MD, Scates SM, Lowe JA, Martin BR. 1995. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. European Journal of Pharmacology 282:R1-2.

4. Adams IB, Martin BR. 1996. Cannabis: pharmacology and toxicology in animals and humans. Addiction 91:1555-1614.

5. Baczynsky WO, Zimmerman AM. 1983a. Effects of delta-9-tetrahydrocannabinol, cannabinol, and cannabidiol on the immune system in mice: I. In vivo investigation of the primary ant secondary immune response Pharmocology 26: 1 - 11 .

6. Baczynsky WO, Zimmerman AM. 1983b. Effects of delta 9-tetrahydrocannabinol, cannabinol and cannabidiol on the immune system in mice. II. In vitro investigation using cultured mouse splenocytes. Pharmacology 26; 12-19.

7. Bass R. Engelhard D, Trembovler V, Shohami E. 1996. A novel nonpsychotropic cannabinoid, HU-211, in the treatment of experimental pneumococcal meningitis. Journal of Infectious Diseases 173:735-738.

8. Beardsley PM, Balster RL, Harris LS. 1986. Dependence on tetrahydrocannabinol in rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics 239:311-319.

9. Ben-Shabat S. Fride E, Sheskin T. Tamiri T. Rhee MH, Vogel Z. Bisogno T. De Petrocellis L, Di Marzo V, Mechoulam R. 1998. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. European Journal of Pharmacology 353 :23-31.

10. Bennett GJ. 1994. Neuropathic Pain. In: Wall PD, Melzack R Editors Textbook of Pain. Edinburgh: Churchill Livingstone.

11. Bird KD, Boleyn T. Chesher GB, Jackson DM, Starmer GA, Teo RKC. 1980. Intercannabinoid and cannabinoid-ethanol interactions and their effects on human performance. Psychopharmacology 71:181-188.

12. Bloom AS, Dewey WL, Harris LS, Brosius KK. 1977. 9-nor-9b- hydroxyhexahydrocannabinol, a cannabinoid with potent antinociceptive activity: Comparisons with morphine. Journal of Pharmacology and Experimental Therapeutics 200:263-270.

13. Bornheim LM, Everhart ET, Li J. Correia MA. 1994. Induction and genetic regulation of mouse hepatic cytochrome P450 by cannabidiol. Biochemical Pharmacology (England) 48:161-171.


14. Bornheim LM, Kim KY, Chen B., Correia MA. 1993. The effect of cannabidiol on mouse hepatic microsomal cytochrome P450-dependent anandamide metabolism. Biochemical and Biophysical Research Communications (United States) 197:740746.

15. Bornheim LM, Kim KY, Li J. Perotti BY, Benet LZ. 1995. Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug Metabolism and Disposition (United States) 23:825-831.

16. Breivogel CS, Sim LJ, Childers SR. 1997. Regional differences in cannabinoid receptor/G-protein coupling in rat brain. Journal of Pharmacology and Experimental Therapeutics 282:1632-1642.

17. British Medical Association. 1997. Therapeutic uses of cannabis. Amsterdam, The Netherlands: Harwood Academic Publishers.

18. Burkey THC Quock RM, Consroe P. Roeske WR, Yamamura H1. 1997. Delta-9 tetrahydrocannabinol is a partial agonist of cannabinoid receptors in mouse brain. European Journal of Pharmacology 323:R3-R4.

19. Buxbaum DM. 1972. Analgesic activity of D9-tetrahydrocannabinol in the rat and mouse. Psychopharmacology 25:275-280.

20. Cabral G A, Dove Pettit D A. 1998. Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease Journal of Neuroimmunology 83:116123.

21. Cabral GA, Lockmuller JC, Mishkin EM. 1986. Delta-9-tetrahydrocannabinol decreases alpha/beta interferon response to herpes simplex virus type 2 in the B6C3F1 mouse. Proceedings of the Society for Experimental Biology and Medicine 181 :305-311.

22. Calignano A, La Rana G. Giuffrida A, Piomelli D. 1998. Control of pain initiation by endogenous cannabinoids. Nature 394:277-281.

23. Campbell KA, Foster TC, Hampson RE, Deadwyler SA. 1986a. Delta-9- tetrahydrocannabinol differentially affects sensory-evoked potentials in the rat dentate gyrus. Journal of Pharmacology and Experimental Therapeutics 239:936--940.

24. Campbell KA, Foster TC, Hapson RE, Deadwyler SA. 1986b. Effects of delta-9- tetrahydrocannabinol on sensory-evoked discharges of granule cells in the dentate gyrus of behaving rats. Journal of Pharmacology and Experimental Therapeutics 239:941 -945.

25. Chen J. Marmur R. Pulles A, Paredes W. Gardner EL. 1993. Ventral segmental microinjection of delta-9-tetrahydrocannabinol enhances ventral segmental somatodendritic dopamine levels but not forebrain dopamine levels: evidence for local neural action by marijuana's psychoactive ingredient. Brain Research 621 :6570.

26. Childers SR. 1997. Opioid receptors: Pinning down the opiate targets. Current Biology 7:R695-R697.


27. Childers SR, Breivogel CS. 1998. Cannabis and endogenous cannabinoid systems. Drug and Alcohol Dependence 51:173-187.

28. Coffey RG, Yamamoto Y. Shella E, Pross S. 1996. tetrahydrocannabinol inhibition of macrophage nitric oxide production. Biochemical Pharmacology 52:743-751.

29. Collins DR, Pertwee RG, Davies SN. 1994. The action of synthetic cannabinoids on the induction of long-term potentiation in the rat hippocampal slice. European Journal of Pharmacology 259:R7-R8.

30. Collins DR, Pertwee RG, Davies SN. 1995. Prevention by the cannabinoid antagonist, SR141716A, of cannabinoid-mediated blockade of long-term potentiation in the rat hippocampal slice. British Journal of Pharmacology 115:869-870.

31. Costa B. Parolaro D, Colleoni M. 1996. Chronic cannabinoid, CP-55,940, administration alters biotransformation in the rat. European Journal of Pharmacology 313: 17-24.

32. Daaka Y. Friedman H. Klein T. 1996. Cannabinoid receptor proteins are increased in Jurkat, human T-Cell line after mitogen activation. Journal of Pharmacology and Experimental Therapeutics 276:776-783.

33. Daaka Y. Zhu W. Friedman H. Klein T. 1997. Induction of interleukin-2 receptor a gene by 9-tetrahydrocannabinol is mediated by nuclear factor kB and CB1 cannabinoid receptor. DNA and Cell Biology 16:301-309.

34. Deadwyler SA, Heyser CJ, Hampson RE. 1995. Complete adaptation to the memory disruptive effects of delta-9-THC following 35 days of exposure. Neuroscience Research Communications 17:9- 18.

35. Derocq JM, Segui M, Marchand J. Le Fur G. Casellas P. 1995. Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS Letters 369:177-182.

36. Devane WA, Dysarc FA, Johnson MR, Melvin LS, Howlett AC. 1988. Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology 34:605-613.

37. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffing F. Gibson D, Mandelbaum A, Etinger A, Mechoulam R. 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946- 1949.

38. Dewey WL. 1986. Cannabinoid pharamacology. Pharmacology Review 38:151-178.

39. Di Chiara G. Imperato A. 1988. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proceedings of the National Academy of Science, USA 85:5274-5278.

40. Dill JA, Howlett AC. 1988. Regulation of adenylate cyclase by chronic exposure to cannabimimetic drugs. Journal of Pharmacology and Experimental Therapeutics 244:1157-1163.

41. Evans DJ, Keith DEJ, Morrison H. Magendzo K, Edwards RH. 1992. Cloning of a delta
opioid receptor by functional expression. Science 258:1952- 1955.


42. Fan F. Tao Q. Abood ME, Martin BR. 1996. Cannabinoid receptor down-regulation without alteration of the inhibitory effect of CP 55,940 on adenylyl cyclase in the cerebellum of CP 55,940-tolerant mice. Brain Research 706: 13-20.

43. Felder CC, Glass M. 1998. Cannabinoid receptors and their endogenous agonists. Annual Reviews of Pharmacology and Toxicology 38: 179-200.

44. Felder CC, Nielsen A, Briley EM, Palkovits M, Priller J. Axelrod J. Nguyen DN, Richardson JM, Riggin RM, Koppel GA, Paul SM, Becker GW. 1996. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Letters 393:231 -5.

45. Fields HL. 1987. Pain. New York: McGraw-Hill.

46. Formukong EA, Evans AT, Evans FJ. 1988. Analgesic and anti-inflammatory activity of constituents of Cannabis sativa L. Inflammation 12:361-371.

47. French ED. 1997. Delta-9-tetrabydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neuroscience Letters 226:159-162.

48. Galiegue S. Mary S. Marchand J. Dussossoy D, Carriere D, Carayon P. Bouaboula M, Shire D, Le Fur G. Casellas P. 1995. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. European Journal of Biochemistry 232:54-61

49. Gessa GL, Mascia MS, Casu MA, Carta G. 1997. Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR 141716A. European Journal of Pharmacology 327:R1-2.

50. Gifford AN, Ashby Jr CR. 1996. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55,212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. Journal of Pharmacology and Experimental Therapeutics 277:1431-1436.

51. Gifford AN, Gardner EL, Ashby CRJ. 1997. The effect of intravenous administration of delta-9-tetrahydrocannabinol on the activity of A10 dopamine neurons recorded in vivo in anesthetized rats. Neuropsychobiology 36:96-99.

52. Glass M, Dragunow M, Faull RLM. 1997. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77:299-318.

53. Hadden JW, Hadden EM, Haddox MK, Goldberg ND. 1972. Guanosine 3':5'-cyclic monophosphates: A possible intracellular mediator of mitogenic influences in Lymphocytes. Proceedings of the National Academy of Sciences 69:3024-3027.

54. Hampson AJ, Grimaldi M, Axelrod J. Wink D. 1998. Cannabidiol and (-)Delta-9- tetrahydrocannabinol are neuroprotective antioxidants. Proceedings of the National Academy of Science of the United States of America 95:8268-8273.

55. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. 1999. Abstinence symptoms following oral THC administration to humans. Psychopharmacology 141:385-394.


56. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. 1999. Abstinence symptoms following smoked marijuana in humans. Psychopharmacology 141 :395-404.

57. Herkenham M. 1995. Localization of cannabinoid receptors in brain and periphery. In: Pertwee RG ed. Cannabinoid Receptors. Academic Press Limited. Pp. 145-166.

58. Herkenham M, Lynn AB, de Costa BR, Richfield EK. 1991a. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Research 547:267-274.

59. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. 1991b. Characterization and localization of cannabinoid receptors in rat brain: a quantative in vitro autoradiographic study. Journal of Neuroscience 11 :563-583.

60. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC. 1990. Cannabinoid receptor localization in the brain. Proceedings of the National Academy of Sciences of the United States of America 87: 1932- 1936.

61. Herring AC, Koh WS, Kaminski NE. 1998. Inhibition of the cyclic AMP signaling cascade and nuclear factor binding to CRE and kappa B elements by cannabinol, a minimally CNS-active cannabinoid. Biochemical Pharmacology 55:1013-1023.

62. Henberg U. Eliav E, Bennett GJ, Kopin IJ. 1997. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neuroscience Letters 221: 157-60.

63. Heyser CJ, Hampson RE, Deadwyler SA. 1993. Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: Alterations in short-term memory associated with changes in task specific firing of hippocampal cells. Journal of Pharmacology and Experimental Therapeutics 264:294-307.

64. Hohmann AG, Briley E M, Herkenham M. in press (1998). Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Research

65. Hohmann AG, Herkenham M. 1998. Regulation of cannabinoid and mu opioid receptor binding sites following neonatal capsaicin treatment. Neuroscience Letters 252: 1316.

66. Hohmann AG, Herkenham M. in press (1998). Localization of central cannabinoid CB1 receptor mRNA in neuronal subpopulations of rat dorsal root ganglia: A double- label in situ hybridization study. Neuroscience

67. Hohmann AG, Martin WJ, Tsou K, Walker JM 1995 Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2. Life Sciences 56:2111-2119.

68. Hollister LE. 1986. Health aspects of cannabis. Pharmacological Reviews 38:1-20.

69. Hollister LE, Gillespie BA. 1975. Interactions in man of delta-9-THC. II. Cannabinol and cannabidiol. Clinical Pharmacology and Therapeutics 18:80-83.


70. Hughes J. Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, Morris HR. 1975. Identification of two related pentapeptides from the brain with potent opiate agonists activity. Nature 258:577-580.

71. Jackson AL, Murphy LL. 1997. Role of the hypothalamic-pituitary-adrenal axis in the suppression of luteinizing hormone release by delta-9-tetrahydrocannabinol. Neuroendocrinology 65:446-452.

72. Jacob J. Rarnabadran K, Campos-Medeiros M. 1981. A pharmacological analysis of levonantradol antinociception in mice. Journal of Clinical Pharmacology 21 :327S-333S.

73. Jaggar SI, Hasnie FS, Sellaturay S. Rice AS. 1998. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 76:189199.

74. Jeon YJ, Yang K-H, Pulaski JT, Kaminski NE. 1996. Attenuation of inducible nitric oxide synthase gene expression by delta-9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor-kB/Rel activation. Molecular Pharmacology 50:334341.

75. Johnson MR, Melvin LS. 1986. The discovery of non-classical cannabinoid analgesics. In: Mechoulam R editor Cannabinoids as therapeutic agents. Boca Raton, FL: CRC Press, Inc. Pp. 121-145.

76. Jones RT, Benowitz NL, Herning RI. 1981. Clinical relevance of cannabis tolerance and dependence. Journal of Clinical Pharmacology 21: 143S-152S.

77. Kaminski NE. 1996. Immune regulation by cannabinoid compounds through the inhibition of the cyclic AMP signaling cascade and altered gene expression. Biochemical Pharmacology 52:1133-1140.

78. Kaminski NE, Abood M E, Kessler F K, Martin B R. Schatz A R. 1992. ldentification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Molecular Pharmacology 42:736-742.

79. Kaminski NE, Koh WS, Yang KH, Lee M, Kessler FK. 1994 Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism. Biochemical Pharmacology 48:1899-1908.

80. Kaminski NE. 1998. Regulation of cAMP cascade, gene expression and immune function by cannabinoid receptors. Journal of Neuroimmunology 83: 124- 132

81. Karniol IG, Shirakawa I, Kasinski N. Pfeferman A, Carlini EA. 1975. Cannabidiol interferes with the effects of delta-9-tetrahydrocannbinol in man. European Journal of Pharmacology 28:172-177.

82. Kieffer BL, Befort K, Gaveriaux-Ruff C, Hirth CG. 1992. The delta-opioid receptor: isolation of a cDNA by expression clining and pharmacological characterization. Proceedings of the National Academy of Sciences of the United States of America 89: 12048-12052.


83. Kirby MT, Hampson RE, Deadwyler SA. 1995. Cannabinoids selectively decrease paired pulse perforant path synaptic potentials in the dentate gyrus in vitro. Brain Research 688:114-120.

84. Klein TW, Friedman H. 1990. Modulation of murine immune cell function by marijuana components. In: Watson R ed. Drugs of Abuse and immune Function. Boca Raton, FL: CRC Press.

85. Klein TW, Friedman H. Specter SC. 1998. Marijuana, immunity and infection. Journal of Neuroimmunology 83: 102- 115.

86. Klein TW, Newton C, Friedman H. 1987. Inhibition of natural killer cell function by marijuana components. Journal of Toxicology and Environmental Health 20:321-332.

87. Klein TW, Newton C, Friedman H. 1994. Resistance to Legionella pneumophila suppressed by the marijuana component, tetrahydrocannabinol Journal of Infectious Diseases 169:1177-1179.

88. Klein TW, Newton C, Friedman H. 1998. Cannabinoid receptors and immunity. Immunology Today 19:373-381.

89. Klein TW, Newton C, Widen R. Friedman H. l985 The effect of delta-9 tetrahydrocannabinol and 11-hydroxy-delta-9-tetrahydrocannabinol on T-lymphocyte and B-lymphocyte mitogen responses. Journal of Immunopharmacology 7:451-466.

90. Klein TW, Newton C, Widen R. Friedman H. 1993. Delta-9-tetrahydrocannabinol injection induces cytokine-mediated mortality of mice infected with Legionella pneumophila. Journal of Pharmacology and Experimental Therapeutics 267:635-640.

91. Koh WS, Yang KH, Kaminski NE. 1995. Cyclic AMP is an essential factor in immune responses. Biochemical and Biophysical Research Communications 206:703-709.

92. Ledent C, Valverde O. Cossu G. Petitet F. Aubert JF, Beslot F in Bohme GA, Imperato A, Pedrazzini T. Roques BP, Vassart G. Fratta W. Parmentier M. 1999. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283:401 -4 .

93. Lee M, Yang KH, Kaminski NE. 1995. Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes. Journal of Pharmacology and Experimental Therupeutics 275:529536.

94. Lepore M, Liu X, Savage V, Matalon D, Gardner EL. 1996. Genetic differences in delta 9- tetrahydrocannabinol-induced facilitation of brain stimulation reward as measured by a rate-frequency curve-shift electrical brain stimulation paradigm in three different rat strains. Life Sciences 58:365-372

95. Lepore M, Vorel SR, Lowinson J. Gardner EL. 1995. Conditioned place preference induced by delta 9-tetrahydrocannabinol: Comparison with cocaine, morphine, and food reward. Life Sciences 56:2073-2080.


96. Lichtman AH, Martin BR. 1991a. Spinal and supraspinal components of cannabinoid-induced antinociception. Journal of Pharmacology and Experimental Therapeutics 258:517-523.

97. Little PJ, Compton DR, Mechoulam R. Martin BR. 1989. Stereochemical effects of 11-OH- delta-8-THC-dimethylheptyl in mice and dogs. Pharmacology Biochemistry Behavior 32:661-666.

98. Lu F. Ou DW. 1989. Cocaine or delta-9-tetrahydrocannabinol does not affect cellular cytotoxicity in vitro. International Journal of Pharmacology 11: 849-852.

99. Luo YD, Patel MK, Wiederhold MD, Ou DW. 1992. Effects of cannabinoids and cocaine on the mitogen-induced transformations of lymphocytes of human and mouse origins. International Journal of lmmunopharmacology 14:49-56.

100. Lyman WD, Sonett JR, Brosnan CFER, Bornstein MB. 1989. Delta 9-tetrahydrocannabinol: a novel treatment fur experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 23:73-81.

101. Mailleux P. Vanderhaeghen JJ. 1992. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 48:655-668.

102. Martin WJ, Hohmann AG, Walker JM. 1996. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: Correlation between electrophysiological and antinociceptive effects. The Journal of Neuroscience 16:6601 -6611.

103. Martin WJ, Patrick SL, Coffin PO, Tsou K, Walker JM. 1995. An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sciences 56:2103-2109.

104. Martin W J. Patrick S L, Coffin PO, Tsou K, Walker J M. 1995. An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sciences 56:2103-2109.

105. Martin WJ, Tsou K, Walker JM. 1998. Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjections into the rostral ventromedial medulla. Neuroscience Letters 242:33-36.

106. Martoletta MC, Cossu G. Fattore L, Gessa GL, Fratta W. 1998. Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice. Neuroscience 85 :327-330.

107. Matsuda L, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. 1990. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561 -564.

108. Mechoulam R. Ben-Shabat S. Hanus L, Ligumsky M, Kaminski NSA, Gopher A, Almog S. Martin BR, Compton D, Pertwee RG, Griffin G. Bayewitch M, Barg in Vogel Z. 1995. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology 50:83-90.


109. Mechoulam R. Hanus L, Fride E. 1998. Towards cannabinoid drugs - revisited. In: Ellis GP, Luscombe DK, Oxford AW eds. Progress in Medicinal Chemistry. v. 35. Amsterdam: Elsevier Science. Pp. 199-243.

110. Meng ID, Manning BH, Martin WJ, Fields HL. 1998. An analgesia circuit activated by cannabinoids. Nature 395:381-383.

111. Miller AS, Walker JM. 1996. Electrophysiological effects of a cannabinoid on neural activity in the globus pallidus. European Journal of Pharmacology 304:29-35.

112. Munro S. Thomas KL, Abu-Shaar M. 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65.

113. Murphy LL, Steger RW, Smith MS, Bartke A. 1990. Effects of delta-9- tetrahydrocannabinol cannabinol and cannabidiol, alone and in combinations, on luteinizing hormone and prolactin release and on hypothalamic neurotransmitters in the male rat. Neuroendocrinology 52:316-321.

1l4. Narimatsu S. Watanabe K, Matsunaga T., Yamamoto I, Imaoka S. Funae Y. Yoshimura H. 1993. Suppression of liver microsomal drug-metabolizing enzyme activities in adult female rats pretreated with cannabidiol Biological and Pharmaceutical Bulletin (Japan) 16:428-430.

115. Newton CA, Klein T. Friedman H. 1994. Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrabydrocannabinol injection. Infection and immunity 62:4015-4020.

116. Norwicky AV, Teyler TJ, Vardaris RM. 1987. The modulation of long-term potentiation by delta-9-tetrahydrocannabinol in the rat hippocampus, in vitro. Brain Research Bulletin 19:663.

117. O'Leary D, Block RI, Flaum M, Boles Ponto LL, Watkins GL, Hichwa RD. 1998. Acute marijuana effects on rCBF and cognition: A PET study. Abstracts - Society for Neuroscience: 28th Annual Meeting. Los Angeles, CA, November 7-12, l998.
Washington, DC: Society for Neuroscience.

118. Ohlsson A, Lindgren J-E, Wahlen A, Agurell S. Hollister L E, Gillespie HK. 1980. Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clinical Pharmacology and Therapeutics

119. Oviedo A, Glowa J. Herkenham M. 1993. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Research 616:293-302

120. Pacheco MA, Ward SJ, Childers SR. 1993. Identification of cannabinoid receptors in cultures of rat cerebellar granule cells. Brain Research 603: 102- 110.

121. Patel V, Borysenko M, Kumar MSA, Millard WJ. 1985. Effects of acute and subchronic delta-9-tetrahydrocannabinol administration on the plasma catecholamine, beta- endorphin, and corticosterone levels and splenic natural killer cell activity in rats. Proceedings of the Society for Experimental Biology and Medicine 180:400-404.


122. Pepe S. Ruggiero A, Tortora G. Ciaardiello F. Garbi C, Yokozaki H. Cho-Chung YS, Clair T. Skalhegg BS, Bianco AR. 1994. Flow cytometric detection of the RT alpha subunit of type-I cAMP-dependent protein kinase in human cells. Cytometry 15:7379.

123. Pert CB, Snyder SH. 1973. Opiate receptor: demonstration in nervous tissue. Science 179:1011-1014.

124. Pertwee RG. 1997b. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacology and Therapeutics 74: 129-180.

125. Pertwee RG, Stevenson LA, Griffin G. 1993. Cross-tolerance between delta-9- tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide [published erratum appears in British Journal of Pharmacology 1994 Mar; 111(3):968]. British Journal of Pharmacology l10:1483-90.

126. Pertwee RG, Wickens AP. 1991. Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids. Neuropharmacology 30:237-244.

127. Pross SH, Nakano Y. Widen R. McHugh S. Newton C, Klein TW, Friedman H. 1992. Differing effects of delta-9-tetrahydrocannabinol (THC) on murine spleen cell populations dependent upon stimulators International Journal of Immunopharmacology 14:1019- 1027.

128. Razdan RK. 1986. Structure-activity relationships in cannabinoids. Pharmacology Review 38 75-149.

129. Rhee MH, Vogel Z. Barg J. Bayewitch M, Levy R. Hanus L, Breuer A, Mechoulam R. 1997. Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylcyclase. Journal of Medicinal Chemistry 40:3228-3233.

130. Richardson JD, Aanonsen L, Hargreaves KM. 1998. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. Journal of Neuroscience 18:451--457.

131. Richardson JD, Kilo S. Hargreaves KM. 1998. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75:111 - 119.

132. Rinaldi-Carmona M, Barth F. Heaulme M, Shire D, Calandra B. Congy C, Martinez S. Maruani J. Neliat G. Caput D, Ferrara P. Soubrie P. Breliere JC, Le Fur G. 1994. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Letters 350:240-244.

133. Rinaldi-Carmona M, Barth F. Millan J. Defrocq J. Casellas P. Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B. Portier M, Shire D, Breliere J. Le Fur G. 1998. SR144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. Journal of Pharmacology and Experimental Therapeutics 284:644-650.

134. Rodriguez de Fonseca F. Fernandez-Ruiz JJ, Murphy LL, Eldridge JC, Steger RW, Bartke A. 1991. Effects of delta-9-tetrahydrocannabinol exposure on adrenal medullary function: evidence of an acute effect and development of tolerance in chronic treatments. Pharmacology, Biochemistry and Behavior 40:593-598


135. Rodriguez de Fonseca F. Carrera MRA, Navarro M, Koob G. Weiss F. 1997. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal [see comments Science 1997. 276:1967-1968]. Science 276:2050-2054.

136. Rodriguez de Fonseca F. Gorriti MA, Fernandez-Ruiz JJ, Palomo T. Ramos JA. 1994. Down-regulation of rat brain cannabinoid binding sites after chronic delta-9- tetrahydrocannabinol treatment. Pharmacology, Biochemistry and Behavior 47:33--40.

137. Romero J. Garcia L, Fernandez-Ruiz JJ, Cebeira M, Ramos JA 1995 Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta-9-tetrahydrocannabinol. Pharmacology, Biochemistry and Behavior 51:731 -737.

138. Romero J. Garcia-Palomero E, Castro JG, Garcia-Gil L, Ramos JA, Fernandez-Ruiz JJ. 1997. Effects of chronic exposure to delta-9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Molecular Brain Research 46: 100-8.

139. Russell DH. 1978. Type I cyclic AMP-dependent protein kinase as a positive effector of growth. Advances in Cyclic Nucleotide Research 9:493-506.

140. Sanudo-Pena M C, Tsou K, Delay E R. Hohmann AG, Force M, Walker JM. 1997. Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. Neuroscience Letters 223: 125- 128.

141. Sanudo-Pena MC, Walker JM. 1997. Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat. Journal of Neurophysiology 77: 1635-1638.

142. Schatz AR, Koh WS, Kaminski, NE. 1993. Delta-9-tetrahydrocannabinol selectively inhibits T-cell dependent humoral immune responses through direct inhibition of accessory T-cell function. Immunopharmacology 26: 129- 137.

143. Schlicker E, Timm J. Zenter J. Goethert M. 1997. Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus. Naunyn-Schmiedeberg's Archives of Pharmacology 356:583-589.

144. Shen M, Piser TM, Seybold VS, Thayer SA. 1996. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. Journal of Neuroscience 16:4322-4334.

145. Shivers S C, Newton C, Friedman H. Klein TW. 1994. Delta 9-tetrahydrocannabinol (THC) modulates IL-1 bioactivity in human monocyte/macrophage cell lines. Life Sciences 54: 1281-1289.

146. Shohami E, Gallily R. Mechoulam R. Bass R. Ben-Hur T. 1997. Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. Journal of Neuroimmunology 72: 169--177.

147. Sim LJ, Hampson RE, Deadwyler SA, Childers SR. 1996. Effects of chronic treatment with delta-9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPyS autoradiography in rat brain. Journal of Neuroscience 16:8057-8066.


148. Sim LJ, Xiao R. Selley DE, Childers SR. 1996. Differences in G-protein activation by mu- and delta-opioid, and cannabinoid, receptors in rat striatum. European Journal of Pharmacology 307:97-105.

149. Simon EJ. 1973. In search of the opiate receptor. American Journal of Medical Sciences 266: 160- 168.

150. Skaper SD, Buriani A, Dal Toso R. Petrelli L, Romanello S. Facci L, Leon A. 1996. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proceedings of the National Academy of Sciences of the United States of America 93:3984-9.

151. Smith JW, Steiner AL, Newberry WM, Parker CW. 1971. Cyclic adenosine 3',5'- monophosphate in human lymphocytes: Alteration after phytohemagglutinin. Journal of Clinical Investigation 50:432-441.

152. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R. Martin BR. 1994. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. Journal of Pharmacology and Experimental Therapeutics 270:219-227.

153. Smith PB, Welch SP, Martin BR. 1994. Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice. Journal of Pharmacology and Experimental Therapeutics 268:1381-1387.

154. Sofia RD, Nalepa SD, Harakal JJ, Vassar HB. 1973. Anti-edema and analgesic properties of delta-9-tetrahydrocannabinol (THC). Journal of Pharmacology and Experimental Therapeutics 186:646-655.

155. Specter S. Lancz C, Hazelden J. 1990. Marijuana and immunity: tetrahydrocannabinol mediated inhibition of lymphocyte blastogenesis. International Journal of Immunopharmacology 12;261-267.

156. Stefano G. Salzet B. Salzet M. 1997. Identification and characterization of the leech CNS cannabinoid receptor: Coupling to nitric oxide release. Brain Research 753:219--224.

157. Stella N. Schweitzer P. Piomelli D. 1997. A second endogenous cannabinoid that modulates long term potentiation. Nature 388:773-778.

158. Strangman NM, Patrick SL, Hohmann AG, Tsou K, Walker JM. 1998. Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity. Brain Research 813:. 323-328.

159. Sulcova C, Mechoulam R., Fride E. 1998. Biphasic effects of anandamide. Pharmacology, Biochemistry and Behavior 59:347-352.

160. Szabo B. Dorner L, Pfreundtner C, Norenberg W. Starke K. 1998. Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus straitum Neuroscience 85:395-403.

161. Tanda G. Pontieri FE, Di Chiara G. 1997. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common µ1 opioid receptor mechanism. Science 276:2048-2049.


162. Terenius L. 1973. Characteristics of the "receptor" for narcotic analgesics in synaptic plasma membrane fraction from rat brain. Acta Pharmacologica Et Toxicologica 33:377-384.

163. Terranova JP, Michaud JC, Le Fur G. Soubrie P. 1995. Inhibition of long-term potentiation in rat hippocampal slice by anandamide and WIN 55.212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors. Naunyn-Schmiedeberg's Archives of Pharmacology 352:576-579.

164. Titishov N. Mechoulam R. Zimmerman AM. 1989. Stereospecific effects of (-) and (+)-7- hydroxy-delta-6-tetrahydrocannabinol-dimethylheptyl on the immune system of mice. Pharmacology 39:337-349.

165. Tsou K, Brown S. Sanudo-Pena MC, Mackie K, Walker JM. 1998. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83:393-411.

166. Tsou K, Patrick SL, Walker JM. 1995. Physical withdrawal in rats tolerant to delta-9- tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. European Journal of Pharmacology 280:R13-R15.

167. Watson PF, Krupinski J. Kempinski A, Frankenfield C. 1994. Molecular cloning and characterization of the type VII isoform of mammalian adenylyl cyclase expressed widely in mouse tissues and in S49 mouse Iymphoma cells. Journal of Biological Chemistry 269:28893-28898.

168. Watzl B. Scuder P. Watson RR. 1991. Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro. International Journal of Immunopharmology 13:1091-1097.

169. Weidenfeld J. Feldman S. Mechoulam R. 1994. Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology 59:110-112.

170. Welch SP. 1993. Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyl-tyrosine-Aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice. Journal of Pharmacology and Experimental Therapeutics 265:633-640.

171. Welch SP, Thomas C, Patrick GS. 1995. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: Possible mechanisms for interaction with morphine. Journal of Clinical and Experimental Therapeutics 272:310-321.

172. Wirguin I, Mechoulam R. Breuer A, Schezen E, Weidenfeld J. Brenner T. 1994. Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology 28 :209-214.

173. Wirth PW, Watson ES, ElSohly M, Turner CE, Murphy JC. 1980. Anti-inflammatory properties of cannabichromene. Life Sciences 26:1991-1995.

174. Yaksh TL. 1981. The antinociceptive effects of intrathecally administered levonantradol and desacetyl-levonantradol in the rat. Journal of Clinical Pharmacology 21 :334S--340S.


175. Yoshida H. Usami N. Ohishi Y. Watanabe K, Yamamoto I, Yoshimura H. 1995. Synthesis and pharmacological effects in mice of halogenated cannabinol derivatives. Chemical and Pharmaceutical Bulletin 42:335-337.

176. Zhu W. Newton C, Daaka Y. Friedman H. Klein TW. 1994. Delta 9-tetrahydrocannabinol enhances the secretion of interleukin I from endotoxin-stimulated macrophages. Journal of Pharmacology and Experimental Therapeutics 270: 1334-1339.

177. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. 1982. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 76:245-250.

178. Zurier R.B., Rossetti RG, Lane JH, Goldberg JM, Hunter SA, Burstein SH 1998. Dimethylheptyl-THC- 11 oic acid: A non-psychoactive antiinflmnmatory agent with a cannabinoid template structure. Arthritis and Rheumatism 41:163- 170.


Chapter 3